The phase 2b/3 clinical trial (NCT05683496) evaluated izokibep versus placebo in non-infectious, non-anterior uveitis.

Devices that are approved through a process that does not require any clinical evidence for FDA authorization should not ...

The firm also has plans for tests beyond sepsis, including for cardiac events and other conditions that are commonly treated in acute care settings.

Omeros' stock is volatile, driven by the potential FDA approval of narsoplimab for HSCT-TMA, despite past setbacks including ...

The following is a summary of “Efficacy and safety of guselkumab in patients with active lupus nephritis: results from a ...

The third criterion, which requires the demonstration of a clinical endpoint that is reasonably likely to predict clinical benefit, has also been met. The EPITOPE Phase 3 study conducted by DBV ...

DBV Technologies (DBVT) stock shot up 29% in post-market after the company said it has aligned with the FDA on an accelerated approval pathway for its peanut allergy patch Viaskin.

DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 ...

A stem cell transplant added to Rituxan did not improve survival for MRD-negative MCL patients in their first remission ...

Clinical Cancer Research publishes articles that focus on innovative clinical and translational research bridging the laboratory and the clinic. Topics include targeted therapies; mechanisms of drug ...

OSE Immunotherapeutics Announces Positive Clinical Progress for Late-Stage Proprietary Cancer Vaccine Tedopi® ARTEMIA: Clinical trial protocol ...